94
CARDIOTONICS AND CORONARY VASODILATORS NURS 1950: Pharmacology I 1

CARDIOTONICS AND CORONARY VASODILATORS

  • Upload
    lilli

  • View
    25

  • Download
    0

Embed Size (px)

DESCRIPTION

CARDIOTONICS AND CORONARY VASODILATORS. NURS 1950: Pharmacology I. Objective 1: describe the relationship of calcium to electrical activity of the heart Resting: Preload: Afterload :. repolarization. Heart dependent upon influx of calcium - PowerPoint PPT Presentation

Citation preview

Page 1: CARDIOTONICS AND CORONARY VASODILATORS

1

CARDIOTONICS AND CORONARY VASODILATORS

NURS 1950: Pharmacology I

Page 2: CARDIOTONICS AND CORONARY VASODILATORS

2

Objective 1: describe the relationship of calcium to electrical activity of the heart

Resting: Preload: Afterload:

Page 3: CARDIOTONICS AND CORONARY VASODILATORS

3

Heart dependent upon influx of calcium Ca+ enters channels in the cardiac cell

membrane and go into the cell along with Na

K+ comes out Cardiac cells contract

repolarization

Page 4: CARDIOTONICS AND CORONARY VASODILATORS

4

Objective 2: describe how the ANS affects the heart rate

Page 5: CARDIOTONICS AND CORONARY VASODILATORS

5

The ANS is the primary controller of heart rate

Cholinergic (parasympathetic) vagal fibers are close to the SA node

Stimulation with acetylcholine slows the heart rate

Page 6: CARDIOTONICS AND CORONARY VASODILATORS

6

Sympathetic (adrenergic) nerves also innervate the heart

Stimulation causes norepinephrine to be released.

Increases heart rate, slows refractory period

Page 7: CARDIOTONICS AND CORONARY VASODILATORS

7

Page 8: CARDIOTONICS AND CORONARY VASODILATORS

8

Objective 3: describe how cardiac drugs affect cardiac action

Page 9: CARDIOTONICS AND CORONARY VASODILATORS

9

1. Increase or decrease the force of myocardial action

Positive inotropics Negative inotropics

How cardiac drugs work

Page 10: CARDIOTONICS AND CORONARY VASODILATORS

10

2. Increase or decrease heart rate by altering SA node impulse conduction

Positive chronotropics Negative chronotropics

Page 11: CARDIOTONICS AND CORONARY VASODILATORS

11

3. Increase or decrease conduction of AV impulses

Positive dromotropics Negative dromotropics

Page 12: CARDIOTONICS AND CORONARY VASODILATORS

12

Diuretics to decrease blood volume

Page 13: CARDIOTONICS AND CORONARY VASODILATORS

Figure 24.1 Pathophysiology of heart failure

Page 14: CARDIOTONICS AND CORONARY VASODILATORS

14

Objective 4: identify the action of cardiac glycosides

Page 15: CARDIOTONICS AND CORONARY VASODILATORS

15

Digoxin & relatives

Come from Natural sources Helpful in CHF Have a positive inotropic effect

Cardiac glycosides

Page 16: CARDIOTONICS AND CORONARY VASODILATORS

16

Increases mechanical efficiency of heart This pumps more blood With increased blood to kidneys, diuresis

occurs, edema reduced Cardiac glycosides also have negative

chronotropic effect, Negative dromotropic effect

Page 17: CARDIOTONICS AND CORONARY VASODILATORS

17

Action◦ Thought that they cause release of free calcium

within the cardiac muscle cell

◦ Also change the electrical activity of myocardium

Page 18: CARDIOTONICS AND CORONARY VASODILATORS

18

Decrease velocity of electrical conduction, prolong refractory period in AV conduction system

Increase vagal tone

Page 19: CARDIOTONICS AND CORONARY VASODILATORS

19

Objective 5: relate how the effects of digitalis are beneficial to the client with CHF

Recall the signs/symptoms of CHF

How do you think cardiac glycosides improve this condition?

Page 20: CARDIOTONICS AND CORONARY VASODILATORS

20

Objective 6: describe the usefulness of digitalis in the treatment of atrial fibrillation

Page 21: CARDIOTONICS AND CORONARY VASODILATORS

21

What is atrial fibrillation? What activity of the cardiac glycosides

improve this condition?

Page 22: CARDIOTONICS AND CORONARY VASODILATORS

22

Chronotropic/dromotropic effects◦ Suppress impulse conduction through the AV node◦ This prevents excessive atrial activity from

reaching ventricles

Page 23: CARDIOTONICS AND CORONARY VASODILATORS

23

Objective 7: list the generic and brand names of the digitalis preparations

Digitalis preparations similar in pharmacological properties, toxic effects

Page 24: CARDIOTONICS AND CORONARY VASODILATORS

24

Digoxin (Lanoxin, Lanoxicaps): oral or IV Onset 30-120 minutes oral Peaks 2-6 hrs Duration 2-4 days Eliminated by kidney

◦ Used most often as rapid onset, short duration

Prototype

Page 25: CARDIOTONICS AND CORONARY VASODILATORS

25

Must take apical pulse 1 minute before administration

Hold if under 60, contact MD Blood levels needed

Page 26: CARDIOTONICS AND CORONARY VASODILATORS

26

Objective 8: define digitalization

Page 27: CARDIOTONICS AND CORONARY VASODILATORS

27

Digitalization is the administration of digitalis that is more than the maintenance dose

This raises the blood level quickly to therapeutic range◦ May also be called a loading dose

Page 28: CARDIOTONICS AND CORONARY VASODILATORS

28

Example◦ Oral dose of digoxin 0.5-0.75 mg◦ 0.25-0.5 mg then given every 6-8 hours until

desired blood level reached◦ Then maintenance dose: 0.125-0.5 mg daily

Page 29: CARDIOTONICS AND CORONARY VASODILATORS

29

Objective 9: list symptoms of digitalis toxicity

Page 30: CARDIOTONICS AND CORONARY VASODILATORS

30

Digitalis toxicity:◦GI distress: N/V, anorexia, and/or diarrhea (flu like symptoms)

◦May have excessive salivation and abdominal pain

◦Neurological: restless, irritable, lethargy, drowsiness, and/or confusion

Page 31: CARDIOTONICS AND CORONARY VASODILATORS

31

May have vision changes, changes in color◦May have halos, amblyopia and diplopia

◦Cardiac effects: development of arrhythmias (bradycardia, primary AV block)

Page 32: CARDIOTONICS AND CORONARY VASODILATORS

32

Objective 10: identify factors which predispose digitalis toxicity

Page 33: CARDIOTONICS AND CORONARY VASODILATORS

33

Toxicity predisposition: hypokalemia as cardiac muscles more sensitive to the glycosides

Renal impairment as 60-90% excreted by kidney

IV administration: rapid accumulation can occur

Contraindications

Page 34: CARDIOTONICS AND CORONARY VASODILATORS

34

Treatment◦ Hold the drug◦ Use digoxin immune fab (Digibind) Antigen-binding fragments combine with digoxin to neutralize its action

Page 35: CARDIOTONICS AND CORONARY VASODILATORS

Lisinopril Animation

Click here to view an animation on the topic of lisinopril.

Page 36: CARDIOTONICS AND CORONARY VASODILATORS

Diuretics Prototype drug: furosemide (Lasix) Mechanism of action: to increase urine

flow, reducing blood volume and cardiac workload

Primary use: to reduce edema and pulmonary congestion

Adverse effects: dehydration, electrolyte imbalance, hypotension, ototoxicity

Page 37: CARDIOTONICS AND CORONARY VASODILATORS
Page 38: CARDIOTONICS AND CORONARY VASODILATORS

Furosemide Animation

Click here to view an animation on the topic of furosemide.

Page 39: CARDIOTONICS AND CORONARY VASODILATORS

Cardiac Glycosides Prototype drug: digoxin (Lanoxin) Mechanism of action: to cause more

forceful heartbeat, slower heart rate Primary use: to increase contractility or

strength of myocardial contraction Adverse effects: neutropenia,

dysrhythmias, digitalis toxicity

Page 40: CARDIOTONICS AND CORONARY VASODILATORS
Page 41: CARDIOTONICS AND CORONARY VASODILATORS

Beta-Adrenergic Blockers Prototype drug: Metoprolol (Lopressor,

Troprol XL) Mechanism of action: block cardiac

action of sympathetic nervous system to slow heart rate and B/P, reducing workload of heart

Primary use: to reduce symptoms of heart failure and slow progression of disease

Adverse effects: fluid retention, worsening of heart failure, fatigue, hypotension, bradycardia, heart block

Page 42: CARDIOTONICS AND CORONARY VASODILATORS
Page 43: CARDIOTONICS AND CORONARY VASODILATORS

Vasodilators Drugs: hydralazine (Apresoline);

(isosorbide dinitrate (Isordil) Mechanism of action: to relax blood

vessels Primary use: to lower blood pressure Used for clients who cannot take ACE

inhibitors Adverse reactions: reflex tachycardia,

orthostatic hypotension

Page 44: CARDIOTONICS AND CORONARY VASODILATORS

Phosphodiesterase Inhibitors Prototype drug: milrinone (Primacor) Mechanism of action: to block enzyme

phosphodiesterase in cardiac and smooth muscle

Primary use: as short-term therapy for heart failure

Adverse effects: hypokalemia, hypotension, ventricular dysrhythmias

Page 45: CARDIOTONICS AND CORONARY VASODILATORS
Page 46: CARDIOTONICS AND CORONARY VASODILATORS

46

Objective 11: describe the nursing responsibilities associated with administering cardiac glycosides preparations

Page 47: CARDIOTONICS AND CORONARY VASODILATORS

47

Take apical pulse 1 full minute Hold if under 60, over 100 in adults Report any evidence of irregular rhythm Observe for toxicity S/S Monitor K+ if on diuretics Encourage K+ rich foods

Page 48: CARDIOTONICS AND CORONARY VASODILATORS

48

Teach client to take pulse Teach S/S of toxicity If hypothyroid, sensitive to digitalis Draw blood levels periodically

Page 49: CARDIOTONICS AND CORONARY VASODILATORS

49

Atherosclerosis narrows heart’s vessels Blood flow impeded Demand exceeds supply = anginal pain

Angina

Page 50: CARDIOTONICS AND CORONARY VASODILATORS

50

Objective 12: describe the actions of the antianginal drugs

Page 51: CARDIOTONICS AND CORONARY VASODILATORS

51

Drugs are used to dilate coronary arteries This brings in oxygen and nutrients Supply = demand so no pain

Goals

Page 52: CARDIOTONICS AND CORONARY VASODILATORS

52

Objective 13: identify the drugs used to treat angina pectoris

Page 53: CARDIOTONICS AND CORONARY VASODILATORS

53

Nitroglycerin Calcium channel blockers Beta blockers ACE inhibitors

Page 54: CARDIOTONICS AND CORONARY VASODILATORS

54

Nitroglycerin drugs Works by relaxing arterial and venous

smooth muscle Dilate coronary arteries

Page 55: CARDIOTONICS AND CORONARY VASODILATORS

55

Liquid nitroglycerin unstable, highly volatile Oral tablets stable, non-explosive Can be given sublingual for rapid,

predictable action Can be transmucosal, aerosol translingual

spray, IV, transdermal

Page 56: CARDIOTONICS AND CORONARY VASODILATORS

56

Transdermal

Page 57: CARDIOTONICS AND CORONARY VASODILATORS

57

Ointment: placed on paper with inches marked off

Amount prescribed placed on the paper, taped into place

4-8 hours of action (Nitro-bid, Nitrol)

Page 58: CARDIOTONICS AND CORONARY VASODILATORS

58

Nitroglycerin patches: worn 12-14 hours “Patch-off” period of 6-12 hours Prevents tolerance (Transderm-Nitro, Nitro-Dur)

Page 59: CARDIOTONICS AND CORONARY VASODILATORS

59

IV nitroglycerin in early treatment, then another form

Page 60: CARDIOTONICS AND CORONARY VASODILATORS

60

Long acting forms for prophylaxis◦ Erythrityl tetranitrate (Cardilate)◦ Pentaerythritol tetranitrate (PETN)

Page 61: CARDIOTONICS AND CORONARY VASODILATORS

61

Objective 14: list the side effects of nitroglycerin

Page 62: CARDIOTONICS AND CORONARY VASODILATORS

62

Tolerance Headache Postural hypotension Dizziness Weakness Syncope

◦ Don’t use alcohol with nitros

Page 63: CARDIOTONICS AND CORONARY VASODILATORS

63

Nitrates can increase intraocular and/or intracranial pressure

Page 64: CARDIOTONICS AND CORONARY VASODILATORS

64

Objective 15: identify the nursing responsibilities associated with administering the nitroglycerin preparations

Page 65: CARDIOTONICS AND CORONARY VASODILATORS

65

Teach: when angina occurs, take 3 tabs in 15 min; if no pain relief, call 911

Keep nitro in original container, cap tightly closed

Store in cool, dry place Rotate sites of topical applications Monitor BP during therapy

Page 66: CARDIOTONICS AND CORONARY VASODILATORS

66

Shelf-life is 6 months. If burning/stinging sensation under tongue, drug still potent

Replace 3 months after opening bottle

Page 67: CARDIOTONICS AND CORONARY VASODILATORS

67

Objective 16: identify the beta-adrenergic blocker used to treat angina

Page 68: CARDIOTONICS AND CORONARY VASODILATORS

68

Page 69: CARDIOTONICS AND CORONARY VASODILATORS

69

Examples: propranolol, Atenolol Decrease heart rate, contractility

◦ Results in reduction of myocardial oxygen consumption

◦ Better if used with nitrates Can not use in COPD, CHF, heart block,

bradycardia, DM

Page 70: CARDIOTONICS AND CORONARY VASODILATORS

70

When used with nitrates, hypotensive episodes more likely to occur

Drugs used◦ Atenolol (Tenormin)--prototype◦ Metoprolol (Lopressor)◦ Nadolol (Corgard)◦ Propranolol (Inderal)

Page 71: CARDIOTONICS AND CORONARY VASODILATORS

71

Objective 17: identify the calcium channel blockers used to treat angina

Page 72: CARDIOTONICS AND CORONARY VASODILATORS

72

Page 73: CARDIOTONICS AND CORONARY VASODILATORS

73

Nifedipine (Adalat, Procardia) Diltiazem HCl (Cardizem, Dilacor SR)--

prototype Verapamil (Calan, Isoptin) Bepridil (Vascor) Nicardipine HCl (Cardene)

Examples: calcium channel blockers

Page 74: CARDIOTONICS AND CORONARY VASODILATORS

74

These drugs create coronary vasodilation, increased coronary blood flow, lowered blood pressure, increased cardiac output, and relax coronary artery spasms

Page 75: CARDIOTONICS AND CORONARY VASODILATORS

Nitrates Prototype drug: nitroglycerin (Nitrostat) Mechanism of action: relax both arterial

and venous smooth muscle; dilate coronary arteries◦ Short acting-terminate acute angina episode◦ Long-acting-decrease severity and frequency of

episodes

Page 76: CARDIOTONICS AND CORONARY VASODILATORS

Nitrates (continued) Primary use: for lowering myocardial

oxygen demand Adverse effects: hypotension, dizziness,

headache, flushing of face, rash

Page 77: CARDIOTONICS AND CORONARY VASODILATORS
Page 78: CARDIOTONICS AND CORONARY VASODILATORS

Beta-Adrenergic Blockers Prototype drug: atenolol (Tenormin) Mechanism of action: to reduce the

cardiac workload by slowing heart rate and reducing contractility

Primary use: for prophylaxis of stable angina

Adverse effects: fatigue, insomnia, drowsiness, impotence, bradycardia, confusion

Page 79: CARDIOTONICS AND CORONARY VASODILATORS
Page 80: CARDIOTONICS AND CORONARY VASODILATORS

Calcium Channel Blockers Prototype drug: diltiazem (Cardizem) Mechanism of action: to reduce cardiac

workload by relaxing arteriolar smooth muscle; dilate coronary arteries

Primary use: for lowering blood pressure; bring more oxygen into myocardium

Adverse effects: hypotension, bradycardia, heart failure, constipation, headaches, dizziness, edema

Page 81: CARDIOTONICS AND CORONARY VASODILATORS
Page 82: CARDIOTONICS AND CORONARY VASODILATORS
Page 83: CARDIOTONICS AND CORONARY VASODILATORS
Page 84: CARDIOTONICS AND CORONARY VASODILATORS

84

Objective 18: identify the ACE inhibitors used to treat angina

Page 85: CARDIOTONICS AND CORONARY VASODILATORS

85

Page 86: CARDIOTONICS AND CORONARY VASODILATORS

86

The angiotensin-converting enzyme inhibitors decrease myocardial oxygen demands

Page 87: CARDIOTONICS AND CORONARY VASODILATORS

87

Captopril (Capoten) Lisinopril (Prinivil)--prototype Ramipril (Altace)

Examples: ACE inhibitors

Page 88: CARDIOTONICS AND CORONARY VASODILATORS

ACE Inhibitors Prototype drug: lisinopril (Prinivil, Zestril) Mechanism of action: to enhance

excretion of sodium and water Primary use: to decrease blood pressure

and reduce blood volume; dilate veins Adverse effects: first-dose hypotension,

cough, hyperkalemia, renal failure

Page 89: CARDIOTONICS AND CORONARY VASODILATORS
Page 90: CARDIOTONICS AND CORONARY VASODILATORS

90

Objective 19: nursing care

Page 91: CARDIOTONICS AND CORONARY VASODILATORS

91

Frequency, nature, precipitants of angina attack

Lifestyle changes made Effectiveness of coronary vasodilators in

relief of pain Monitor VS, esp. BP

Assessment

Page 92: CARDIOTONICS AND CORONARY VASODILATORS

92

Ineffective tissue perfusion, cardiac function RT angina

Risk for injury RT side effects of coronary vasodilators

Deficient knowledge RT health alteration and medication regimen

Nursing diagnoses

Page 93: CARDIOTONICS AND CORONARY VASODILATORS

93

Client will◦ Verbalize decrease in attacks◦ Not experience injury due to coronary

vasodilitation◦ Verbalize s/s of drug toxicity and report to MD

Goals

Page 94: CARDIOTONICS AND CORONARY VASODILATORS

94

What teaching is done for clients taking nitroglycerin?

What teaching is done for clients taking calcium channel blockers, ACE inhibitors, beta blockers?

What will the nurse monitor when clients are on these medications?

Implementation